Media stories about Asterias Biotherapeutics (NYSE:AST) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Asterias Biotherapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.0185660852655 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Asterias Biotherapeutics (AST) remained flat at $3.50 during mid-day trading on Tuesday. 15,388 shares of the company’s stock were exchanged. The firm’s market capitalization is $172.42 million. The stock has a 50 day moving average of $3.49 and a 200-day moving average of $3.50. Asterias Biotherapeutics has a 52-week low of $2.54 and a 52-week high of $5.80.

AST has been the topic of a number of research analyst reports. HC Wainwright set a $12.00 price target on Asterias Biotherapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Insider Buying and Selling by Quarter for Asterias Biotherapeutics (NYSE:AST)

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.